Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2014 06:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG

RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex...